The expression of death receptor 6 (
DR
6) is abnormal in some cancer types, but the function and underlying molecular mechanisms of
DR
6 in tumor progression are not yet clear. In the present study, our analysis of ovarian cancer
RNA
sequencing data from The Cancer Genome Atlas revealed that
DR
6 is upregulated in human ovarian cancer. We confirmed that the expression level of
DR
6 is upregulated in ovarian cancer tissues when compared with matched adjacent normal tissues. In addition,
DR
6 enhanced ovarian carcinoma cell migration ability, and decreased expression of
DR
6 inhibited the expression of matrix metalloprotease (
MMP
) 2 and
MMP
9, and increased the expression of E‐cadherin. Additionally,
DR
6 sh
RNA
caused a significant decrease in phosphoinositide‐3‐kinase (
PI
3K), phospho (p) ‐
AKT
, p‐extracellular signal‐regulated kinase (
ERK
), and p‐mitogen‐activated protein kinase kinase expression in
SKOV
3 cells. These results suggested that
DR
6 can enhance ovarian carcinoma cell migration ability through the mitogen‐activated protein kinase/
ERK
and
PI
3K/
AKT
pathways. Notably, mass spectrometric analysis indicated that
DR
6 co‐purified with kinesin family member 11 (
KIF
11), and we verified the interaction between
KIF
11 and
DR
6 by co‐immunoprecipitation and glutathione
S
‐transferase pull‐down. Furthermore, we demonstrated that
DR
6 can bind tumor necrosis factor receptor‐associated factor 4 (
TRAF
4) with co‐immunoprecipitation. Overexpression of
KIF
11 or
TRAF
4 eliminated the suppression of carcinoma cell migration by
DR
6 knockdown. We also found that
TRAF
4 and
KIF
11 were upregulated in ovarian carcinomas and that their level of expression was positively correlated with that of
DR
6. The findings above suggest that
DR
6 may play a notable oncogenic role in ovarian malignancy by interacting with
TRAF
4 and
KIF
11, and that
DR
6 may be an effective therapeutic target in ovarian cancer.